2025 Q3 -tulosraportti
44 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
2 380
Myynti
Määrä
2 504
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 392 | NON | NON | ||
| 11 | NON | NON | ||
| 50 | NON | NON | ||
| 10 | AVA | NON | ||
| 3 504 | NON | NON |
Ylin
12,85VWAP
Alin
12VaihtoMäärä
1,1 86 551
VWAP
Ylin
12,85Alin
12VaihtoMäärä
1,1 86 551
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 554 | 250 | +4 304 | 0 |
| Danske Bank A/S | 7 178 | 5 000 | +2 178 | 0 |
| Skandinaviska Enskilda Banken AB | 397 | 0 | +397 | 0 |
| Svenska Handelsbanken AB | 250 | 0 | +250 | 0 |
| Avanza Bank AB | 1 452 | 1 677 | −225 | 136 |
| SSW Market Making GmbH | 101 | 1 798 | −1 697 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 72 869 | 78 076 | −5 207 | 64 996 |
| SSW Market Making GmbH | 101 | 1 798 | −1 697 | 0 |
| Avanza Bank AB | 1 452 | 1 677 | −225 | 136 |
| Svenska Handelsbanken AB | 250 | 0 | +250 | 0 |
| Skandinaviska Enskilda Banken AB | 397 | 0 | +397 | 0 |
| Danske Bank A/S | 7 178 | 5 000 | +2 178 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 t sittenI'm playing around a bit with Gemini regarding an upcoming, potential partnership agreement concerning uTREAT / brain cancer. I've asked the bot to compare it with the current partnership agreement with Curium (prostate cancer). When do you here think we'll see a partnership agreement in place? Within 1-2 months? Or will Curasight delay the partnership agreement until ~ May/June, when Phase 1 concludes (or even longer, I wonder)? The analysis is here...it looks quite reasonable...: "Based on the existing agreement with Curium and the latest clinical data for uTREAT®, a qualified comparison can be made of what a future partnership agreement could potentially entail. Here is a direct comparison between the current Curium agreement and the potential that uTREAT® (therapy) possesses: 1. Comparison of agreement values: Curium agreement (uTRACE®) Product: uTRACE® (Diagnostics) Application: Prostate cancer (specific indication) Total value: Up to 70 million USD (~480 million DKK) Milestones: Development and commercial goals Royalties: "Double-digit" (typically 10-15%) Potential uTREAT® agreement Product: uTREAT® (Therapy) Application: Aggressive tumors (e.g. Glioblastoma) Total value: Significantly higher (estimated 300-600+ million USD) Milestones: Larger "upfront" and clinical milestones Royalties: Often higher for therapy (e.g. 15-20%+) 2. Why uTREAT® is more valuable than uTRACE®: There are three main reasons why an agreement based on the news from January 12, 2026, is expected to significantly exceed the Curium agreement: Therapy vs. Diagnostics: Historically, the market for cancer treatment (therapy) is many times larger than the market for diagnostics (scanning). While diagnostics helps find cancer, it is therapy that costs the most and creates the greatest value for pharmaceutical companies. As mentioned in market analyses, the market for glioblastoma treatment is estimated at over 5 billion EUR, while the diagnostics market is significantly smaller. "First-in-class" validation: The news from January 12 confirms for the first time in humans that uTREAT® actually reaches the brain tumor. This enormously reduces the risk ("de-risking") for a partner. The Curium agreement only covered uTRACE for one specific type of cancer (prostate), while uTREAT® can potentially be used for almost all solid tumors (>85%). Platform potential: A partnership agreement for uTREAT® will likely be structured as a "multi-indication" agreement. This means that the value can escalate quickly if the agent also shows effect in, for example, lung cancer or pancreatic cancer. 3. Estimation of size: If Curasight lands a partnership agreement for uTREAT® after their top-line data in Q2 2026, analysts will often look at similar agreements in the radiopharmaceuticals sector (such as Novartis' acquisitions or partnerships). Upfront payment: For uTRACE (Curium), the first milestones were relatively small (e.g. 500,000 USD). For uTREAT®, an upfront payment will likely be in the millions (USD) immediately to secure the rights. Total framework: A total agreement framework of 300-500 million USD is not unrealistic for a promising therapeutic candidate in the early clinical phases, when the platform is already diagnostically validated. Conclusion: A partnership agreement for uTREAT® will likely make the Curium agreement look like a "little brother". While the Curium agreement validated the technology, it is uTREAT® that will drive the really big economic value. Based on links and market practice, we can expect an agreement that is 5-10 times larger in total potential value than the current agreement with Curium.
·3 t sittenIs anyone else wondering why the stock isn't reacting more to the latest positive news, which otherwise removed significant uncertainty in the case - and that it's even falling today? 🤔
·3 t sittenSo, 60 new owners came in yesterday, that's pretty good. It should rise and it will do so again soon (I think). There's always one or 2 who need cash and therefore sell off. New house, new car, expensive divorce etc ... life.
·3 t sittenI'm close to selling my car, renting out the house and marrying rich, so I can buy more shares 😂
·21 t sittenGood revenue. If they can follow up now with something new and perhaps something in the pipeline, then it will suddenly get wild.
·1 päivä sittenBiostock regarding CURAS: https://www.biostock.se/en/2026/01/curasight-presenterar-preliminara-fas-i-data-for-utreat/23 t sitten23 t sitten
·1 päivä sitten · MuokattuLet it fly now, we were at 13.5kr in December. Not this nonsense here 🤷😎
·19 t sittenWhen there's good news,,,, Buy! Bad news Sell! Don't they learn that in the online course? 😁
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
44 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenI'm playing around a bit with Gemini regarding an upcoming, potential partnership agreement concerning uTREAT / brain cancer. I've asked the bot to compare it with the current partnership agreement with Curium (prostate cancer). When do you here think we'll see a partnership agreement in place? Within 1-2 months? Or will Curasight delay the partnership agreement until ~ May/June, when Phase 1 concludes (or even longer, I wonder)? The analysis is here...it looks quite reasonable...: "Based on the existing agreement with Curium and the latest clinical data for uTREAT®, a qualified comparison can be made of what a future partnership agreement could potentially entail. Here is a direct comparison between the current Curium agreement and the potential that uTREAT® (therapy) possesses: 1. Comparison of agreement values: Curium agreement (uTRACE®) Product: uTRACE® (Diagnostics) Application: Prostate cancer (specific indication) Total value: Up to 70 million USD (~480 million DKK) Milestones: Development and commercial goals Royalties: "Double-digit" (typically 10-15%) Potential uTREAT® agreement Product: uTREAT® (Therapy) Application: Aggressive tumors (e.g. Glioblastoma) Total value: Significantly higher (estimated 300-600+ million USD) Milestones: Larger "upfront" and clinical milestones Royalties: Often higher for therapy (e.g. 15-20%+) 2. Why uTREAT® is more valuable than uTRACE®: There are three main reasons why an agreement based on the news from January 12, 2026, is expected to significantly exceed the Curium agreement: Therapy vs. Diagnostics: Historically, the market for cancer treatment (therapy) is many times larger than the market for diagnostics (scanning). While diagnostics helps find cancer, it is therapy that costs the most and creates the greatest value for pharmaceutical companies. As mentioned in market analyses, the market for glioblastoma treatment is estimated at over 5 billion EUR, while the diagnostics market is significantly smaller. "First-in-class" validation: The news from January 12 confirms for the first time in humans that uTREAT® actually reaches the brain tumor. This enormously reduces the risk ("de-risking") for a partner. The Curium agreement only covered uTRACE for one specific type of cancer (prostate), while uTREAT® can potentially be used for almost all solid tumors (>85%). Platform potential: A partnership agreement for uTREAT® will likely be structured as a "multi-indication" agreement. This means that the value can escalate quickly if the agent also shows effect in, for example, lung cancer or pancreatic cancer. 3. Estimation of size: If Curasight lands a partnership agreement for uTREAT® after their top-line data in Q2 2026, analysts will often look at similar agreements in the radiopharmaceuticals sector (such as Novartis' acquisitions or partnerships). Upfront payment: For uTRACE (Curium), the first milestones were relatively small (e.g. 500,000 USD). For uTREAT®, an upfront payment will likely be in the millions (USD) immediately to secure the rights. Total framework: A total agreement framework of 300-500 million USD is not unrealistic for a promising therapeutic candidate in the early clinical phases, when the platform is already diagnostically validated. Conclusion: A partnership agreement for uTREAT® will likely make the Curium agreement look like a "little brother". While the Curium agreement validated the technology, it is uTREAT® that will drive the really big economic value. Based on links and market practice, we can expect an agreement that is 5-10 times larger in total potential value than the current agreement with Curium.
- ·3 t sittenIs anyone else wondering why the stock isn't reacting more to the latest positive news, which otherwise removed significant uncertainty in the case - and that it's even falling today? 🤔·3 t sittenSo, 60 new owners came in yesterday, that's pretty good. It should rise and it will do so again soon (I think). There's always one or 2 who need cash and therefore sell off. New house, new car, expensive divorce etc ... life.·3 t sittenI'm close to selling my car, renting out the house and marrying rich, so I can buy more shares 😂
- ·21 t sittenGood revenue. If they can follow up now with something new and perhaps something in the pipeline, then it will suddenly get wild.
- ·1 päivä sittenBiostock regarding CURAS: https://www.biostock.se/en/2026/01/curasight-presenterar-preliminara-fas-i-data-for-utreat/23 t sitten23 t sitten
- ·1 päivä sitten · MuokattuLet it fly now, we were at 13.5kr in December. Not this nonsense here 🤷😎·19 t sittenWhen there's good news,,,, Buy! Bad news Sell! Don't they learn that in the online course? 😁
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
2 380
Myynti
Määrä
2 504
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 392 | NON | NON | ||
| 11 | NON | NON | ||
| 50 | NON | NON | ||
| 10 | AVA | NON | ||
| 3 504 | NON | NON |
Ylin
12,85VWAP
Alin
12VaihtoMäärä
1,1 86 551
VWAP
Ylin
12,85Alin
12VaihtoMäärä
1,1 86 551
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 554 | 250 | +4 304 | 0 |
| Danske Bank A/S | 7 178 | 5 000 | +2 178 | 0 |
| Skandinaviska Enskilda Banken AB | 397 | 0 | +397 | 0 |
| Svenska Handelsbanken AB | 250 | 0 | +250 | 0 |
| Avanza Bank AB | 1 452 | 1 677 | −225 | 136 |
| SSW Market Making GmbH | 101 | 1 798 | −1 697 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 72 869 | 78 076 | −5 207 | 64 996 |
| SSW Market Making GmbH | 101 | 1 798 | −1 697 | 0 |
| Avanza Bank AB | 1 452 | 1 677 | −225 | 136 |
| Svenska Handelsbanken AB | 250 | 0 | +250 | 0 |
| Skandinaviska Enskilda Banken AB | 397 | 0 | +397 | 0 |
| Danske Bank A/S | 7 178 | 5 000 | +2 178 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
2025 Q3 -tulosraportti
44 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 t sittenI'm playing around a bit with Gemini regarding an upcoming, potential partnership agreement concerning uTREAT / brain cancer. I've asked the bot to compare it with the current partnership agreement with Curium (prostate cancer). When do you here think we'll see a partnership agreement in place? Within 1-2 months? Or will Curasight delay the partnership agreement until ~ May/June, when Phase 1 concludes (or even longer, I wonder)? The analysis is here...it looks quite reasonable...: "Based on the existing agreement with Curium and the latest clinical data for uTREAT®, a qualified comparison can be made of what a future partnership agreement could potentially entail. Here is a direct comparison between the current Curium agreement and the potential that uTREAT® (therapy) possesses: 1. Comparison of agreement values: Curium agreement (uTRACE®) Product: uTRACE® (Diagnostics) Application: Prostate cancer (specific indication) Total value: Up to 70 million USD (~480 million DKK) Milestones: Development and commercial goals Royalties: "Double-digit" (typically 10-15%) Potential uTREAT® agreement Product: uTREAT® (Therapy) Application: Aggressive tumors (e.g. Glioblastoma) Total value: Significantly higher (estimated 300-600+ million USD) Milestones: Larger "upfront" and clinical milestones Royalties: Often higher for therapy (e.g. 15-20%+) 2. Why uTREAT® is more valuable than uTRACE®: There are three main reasons why an agreement based on the news from January 12, 2026, is expected to significantly exceed the Curium agreement: Therapy vs. Diagnostics: Historically, the market for cancer treatment (therapy) is many times larger than the market for diagnostics (scanning). While diagnostics helps find cancer, it is therapy that costs the most and creates the greatest value for pharmaceutical companies. As mentioned in market analyses, the market for glioblastoma treatment is estimated at over 5 billion EUR, while the diagnostics market is significantly smaller. "First-in-class" validation: The news from January 12 confirms for the first time in humans that uTREAT® actually reaches the brain tumor. This enormously reduces the risk ("de-risking") for a partner. The Curium agreement only covered uTRACE for one specific type of cancer (prostate), while uTREAT® can potentially be used for almost all solid tumors (>85%). Platform potential: A partnership agreement for uTREAT® will likely be structured as a "multi-indication" agreement. This means that the value can escalate quickly if the agent also shows effect in, for example, lung cancer or pancreatic cancer. 3. Estimation of size: If Curasight lands a partnership agreement for uTREAT® after their top-line data in Q2 2026, analysts will often look at similar agreements in the radiopharmaceuticals sector (such as Novartis' acquisitions or partnerships). Upfront payment: For uTRACE (Curium), the first milestones were relatively small (e.g. 500,000 USD). For uTREAT®, an upfront payment will likely be in the millions (USD) immediately to secure the rights. Total framework: A total agreement framework of 300-500 million USD is not unrealistic for a promising therapeutic candidate in the early clinical phases, when the platform is already diagnostically validated. Conclusion: A partnership agreement for uTREAT® will likely make the Curium agreement look like a "little brother". While the Curium agreement validated the technology, it is uTREAT® that will drive the really big economic value. Based on links and market practice, we can expect an agreement that is 5-10 times larger in total potential value than the current agreement with Curium.
- ·3 t sittenIs anyone else wondering why the stock isn't reacting more to the latest positive news, which otherwise removed significant uncertainty in the case - and that it's even falling today? 🤔·3 t sittenSo, 60 new owners came in yesterday, that's pretty good. It should rise and it will do so again soon (I think). There's always one or 2 who need cash and therefore sell off. New house, new car, expensive divorce etc ... life.·3 t sittenI'm close to selling my car, renting out the house and marrying rich, so I can buy more shares 😂
- ·21 t sittenGood revenue. If they can follow up now with something new and perhaps something in the pipeline, then it will suddenly get wild.
- ·1 päivä sittenBiostock regarding CURAS: https://www.biostock.se/en/2026/01/curasight-presenterar-preliminara-fas-i-data-for-utreat/23 t sitten23 t sitten
- ·1 päivä sitten · MuokattuLet it fly now, we were at 13.5kr in December. Not this nonsense here 🤷😎·19 t sittenWhen there's good news,,,, Buy! Bad news Sell! Don't they learn that in the online course? 😁
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
2 380
Myynti
Määrä
2 504
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 392 | NON | NON | ||
| 11 | NON | NON | ||
| 50 | NON | NON | ||
| 10 | AVA | NON | ||
| 3 504 | NON | NON |
Ylin
12,85VWAP
Alin
12VaihtoMäärä
1,1 86 551
VWAP
Ylin
12,85Alin
12VaihtoMäärä
1,1 86 551
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 554 | 250 | +4 304 | 0 |
| Danske Bank A/S | 7 178 | 5 000 | +2 178 | 0 |
| Skandinaviska Enskilda Banken AB | 397 | 0 | +397 | 0 |
| Svenska Handelsbanken AB | 250 | 0 | +250 | 0 |
| Avanza Bank AB | 1 452 | 1 677 | −225 | 136 |
| SSW Market Making GmbH | 101 | 1 798 | −1 697 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 72 869 | 78 076 | −5 207 | 64 996 |
| SSW Market Making GmbH | 101 | 1 798 | −1 697 | 0 |
| Avanza Bank AB | 1 452 | 1 677 | −225 | 136 |
| Svenska Handelsbanken AB | 250 | 0 | +250 | 0 |
| Skandinaviska Enskilda Banken AB | 397 | 0 | +397 | 0 |
| Danske Bank A/S | 7 178 | 5 000 | +2 178 | 0 |